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doi:10.1016/j.ejvs.2009.01.008Abstract Background: Cilostazol has proven efficacy in increasing walking distance in claudi-
cants, but it has not been demonstrated to be more effective than placebo in secondary
cardiovascular prevention. The direct effect of exercise on platelet function remains less well
defined. We have investigated the effect of combination treatment with aspirin and cilostazol
on platelet activity in claudicants subjected to repeated treadmill exercise.
Methods: Nineteen claudicants completed a double-blind, randomised, controlled, cross-over
trial. Each subject received a 2-week course of aspirin (75 mg) and placebo and aspirin and
cilostazol (100 mg twice daily). Following each 2-week treatment period, patients participated
in a standardised treadmill test (3.2 km h1, 10 incline) walking to maximal claudication
distance. The exercise was repeated thrice in total, and blood was sampled before and after
exercise. Platelet activation was measured using free platelet counting aggregation, flow
cytometry for surface markers of platelet activation and soluble P-selectin assay.
Results: Compared to aspirin and placebo, combination treatment with aspirin and cilostazol
was associated with reduced arachidonic-acid-induced platelet aggregation (p< 0.01, Wilcox-
on signed-rank test). Aspirin and placebo treatment were associated with elevated P-selectin
expression, platelet-monocyte aggregation and reduced CD42b expression (p< 0.05, Wilcoxon
signed-rank test) post-exercise. No difference was seen in spontaneous platelet aggregation
whilst soluble P-selectin was reduced post-exercise with combination treatment with aspirin
and cilostazol (p< 0.05, Wilcoxon signed-rank test).
Conclusions: Combination treatment with aspirin and cilostazol results in suppression of
platelet activation and reduces the effect of exercise on platelets. The benefit seen may be
a result of cilostazol enhancing the inhibitory effect of aspirin on the cyclo-oxygenase
pathway.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Northern Vascular Centre, Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK. Tel.: þ1912336161.
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Combined Aspirin and Cilostazol Treatment 605Cilostazol is a type III phosphodiesterase inhibitor licensed committee approvals were obtained. The study was per-for use in intermittent claudication. A meta-analysis of
eight multicentre drug trials involving over 2700 claudicants
has indicated that cilostazol is beneficial in improving both
initial and absolute claudication distance.1 Comparable
results have also been reported by a Cochrane review.2
By inhibiting phosphodiesterases, cilostazol prevents the
hydrolysis of cyclic adenosine monophosphate (cAMP). The
consequential rise in intracellular cAMP is responsible for its
antiplatelet and vasodilatory properties.3 In addition, cAMP
is an inhibitor of the cyclo-oxygenase pathway, and hence
reduces production of TxA2. Within vascular smooth
muscle, cAMP inhibits the release of stored intracellular
Ca2þ, and hence suppresses the activity within contractile
proteins. While the direct antiplatelet effects of cilostazol
have been confirmed, any possible clinical benefits require
further work.4 In the context of coronary artery disease,
a beneficial effect has been seen in the prevention of
restenosis after percutaneous coronary intervention.5,6
Compared to placebo, cilostazol has also been shown to be
useful in the prevention of secondary stroke, although
there was not a significant benefit over aspirin.7e9 Although
the risk of intra- and post-operative bleeding requires
further investigation, the results of a study by Wilhite et al.
reassuringly suggested cilostazol does not significantly
prolong bleeding time.10
Although the effect of a combination therapy with
aspirin remains undefined, any synergistic antiplatelet
effect may support the use of cilostazol in patients with
peripheral arterial disease (PAD). Further studies are
needed to ascertain both the antiplatelet effect of
combination therapy and the potential clinical benefits.
This study was performed as a pilot study to assess whether
combination therapy with cilostazol and aspirin had an
antiplatelet effect that exceeded that of aspirin alone and
attenuated the increased platelet activation seen in PAD
patients following exercise.
Materials and Methods
Study design
A double-blind, randomised, placebo-controlled, cross-over
trial design was used. A cross-over design was chosen to
account for any potential confounding effects of smoking,
co-morbidities and medication on platelet function. Using
a table of block randomisation, patients were randomised
to start either aspirin/placebo or aspirin/cilostazol and
then treated with the alternative combination therapy.
Both the patient and the principal investigator were blin-
ded. Treatment packs were dispensed by the hospital
pharmacy. The treatment regimens revealed only after the
completion of the study by all participants and analysis of
the assays. Each patient was subjected to a 14-day period
of treatment with aspirin (75 mg) and placebo (twice daily)
and aspirin and cilostazol (100 mg twice daily). A 10-day
‘washout’ period was allowed between treatments. On the
final day of each treatment, the patients were brought to
the hospital and performed a standardised treadmill test
with blood sampling as previously described.11 The local
ethical committee and the Research and Developmentformed according to the declaration of Helsinki. PAD
patients with symptoms of intermittent claudication were
recruited from outpatients. All patients were treated with
75 mg aspirin daily, prior to recruitment, as part of their
routine antiplatelet therapy.
Inclusion and exclusion criteria
Patients were included if they had PAD with intermittent
claudication, ankleebrachial pressure index (ABPI)< 0.9
and a radiologically (either angiographically or with duplex)
proven lower limb disease. All patients were aged between
40 and 80 years, were able to complete a treadmill exercise
test and were on 75 mg aspirin (prior to commencement of
cilostazol or placebo) as part of their routine antiplatelet
therapy. Patients were excluded if they had any other co-
morbidities known to alter platelet activity. Specifically,
chronic renal failure, diabetes mellitus, invasive malig-
nancy, current infectious process (including gangrene),
platelet count <150 or >450 and any concurrent platelet
disorders were the exclusion criteria. Patients taking
steroids, anticoagulants and antiplatelet agents (other than
aspirin) were also excluded. Patients with co-morbidities
preventing completion of a treadmill test, for example,
arthritis, pulmonary disease and heart failure, were also
excluded. Cilostazol is metabolised by hepatic cytochrome
P-450 enzymes, hence patients taking any medication that
induced or inhibited cytochrome P-450 activity were also
excluded.
Treadmill testing
Patients were asked to remain on clear fluids only for 12 h
prior to attending hospital for the treadmill test, aimed at
minimising the effect of dietary agents on platelet activity.
Transport to the hospital was provided, and, on arrival,
patients were rested supine for 90 min prior to the tread-
mill test (3.2 km h1 at a 10 incline). All participants were
asked to walk to their maximal claudication distance. This
was repeated thrice in total with brief rest periods in
between to allow resolution of calf pain. Blood samples
were taken before commencement of exercise and after
completion of all exercises (1 min and 40 min after
completion of the third cycle of claudication, respectively).
Assessment of platelet activation
Platelet activation was assessed by a variety of methods.
Flow cytometry was used to measure the expression of
platelet P-selectin, glycoprotein (GP) Ib-IX-V and platelete
monocyte aggregates (PMAs). Whole blood free platelet
aggregation was used to measure spontaneous platelet
aggregation and arachidonic acid (AA)-induced aggregation.
ELISA was used to quantify changes in soluble P-selectin.
Flow cytometry was performed using a whole-blood two-
colour staining technique to quantify platelet P-selectin and
GP Ib-IX-V. The method for P-selectin has been previously
described.11,12 GP Ib-IX-V expression was measured with
a similar technique but using fluorescein isothiocyanate
(FITC)-conjugated CD61 antibodies (Dako, Cambridgeshire,
Table 1 Baseline characteristics of claudicants.
nZ 19
Age, years (Range) 64 (53e81)
Gender (M/F) 16/3
Ankleebrachial pressure index (range) 0.6(0.5e0.8)
Risk factors
Smoking, n (%) 10 (53)
Hypercholesterolaemia, n (%) 11 (58)
Hypertension, n (%) 9 (47)
Ischaemic heart disease, n (%) 5 (26)
Medications
b-blockers, n (%) 3 (16)
Calcium channel blockers, n (%) 6 (32)
Statins, n (%) 9 (47)
Ace inhibitors, n (%) 4 (21)
Diuretics, n (%) 5 (26)
Nitrates, n (%) 2 (11)
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CD42b antibody (Dako, Cambridgeshire, UK) to quantify GP
Ib-IX-V complex. Then, 15 000 platelet events were
collected, and the results were expressed as percentage
cells positive for P-selectin and relativemedian fluorescence
(RMF) for GP Ib-IX-V. A whole-blood three-colour staining
technique was used for PMA estimation as previously
described.13 Following a collection of 30 000 events the
results were expressed as percentage cells positive for the
anti-CD61 antibody. For each marker, isotypic control
samples were run in parallel.
Whole blood free platelet aggregation was measured
using the method previously described by Robless et al.14
This technique measures percentage reduction in platelets
following stirring of blood using a platelet aggregometer
(Chronolog Whole blood Aggregometer 590-2D, Chronolog,
Havertown, PA, USA). Platelet count was measured using
the whole blood platelet Coulter counter (Coulter T-890
counter, Coulter Electronics, Luton, UK). Spontaneous
platelet aggregation (SPA) was measured using 0.9% saline
in the absence of an agonist, whilst AA-induced aggregation
was produced by the addition of 0.25 mM AA (Chronolog,
Havertown, PA, USA).
Soluble P-selectin was measured by ELISA with
a commercially available kit (R&D systems, Oxon, UK). The
assay was performed according to the manufacturer’s
instructions using a fully automated technique (Best 2000,
Biokit ELISA systems, Barcelona, Spain).
Statistical analysis
Data were analysed using Minitab (release 13.1) and Prism
(version 3.03). Deviations from Gaussian distribution were
assessed using the AndersoneDarlington test. For inter-
group analysis, a Wilcoxon signed-rank test was used for
data which were non-parametrically distributed, and the
results expressed as the median value with the inter-
quartile range (IQR).
Results
In this study, 22 patients were recruited. Risk factors and
demographics for PAD and medication are summarised in
Table 1. Two patients were unable to complete the treat-
ment due to headaches. One of these patients was identi-
fied to be treated with the placebo and the other with
cilostazol. One patient failed to attend the treadmill test
and withdrew from the study. Hence, 19 patients were able
to complete the trial and were included in the analysis. The
median (range) age was 64 (53e81) years and the ratio of
men to women was 16:3. All data were non-parametrically
distributed.
Surface P-selectin expression (Fig. 1)
A significant increase in P-selectin expression (pZ 0.023)
was seen in the aspirineplacebo group 1 min post-exercise
(1.8%; IQR: 1.1e3.2% positive cells) compared to the pre-
exercise value (1.4%; IQR: 0.7e2.7% positive cells). The 1-
min post-exercise was also significantly higher (pZ 0.018)
than the 40-min post-exercise (1.3%; IQR: 0.7e2.4% positivecells). The same affect was not seen in the aspirine
cilostazol group.
Glycoprotein Ib-IX-V receptor expression (Fig. 2)
Platelet activation is indicated by a reduction in the
expression of the GP Ib-IX-V complex. This is a consequence
of receptor internalisation following binding of the anti-
CD42b antibody. Only with the aspirineplacebo treatment
was the reduction in RMF 1 min post-exercise (41.1; IQR:
34.9e54.3) statistically significant (pZ 0.015) from the
pre-exercise value (55.7; IQR: 46.6e70.4). Following
aspirinecilostazol treatment, there was a marginal drop in
the RMF at 40 min (56.3; IQR: 45.3e77.0) which was found
to be significantly lower (pZ 0.046) than the pre-exercise
value (57.3; IQR: 33.4e67.3). No statistically significant
difference was identified between the two treatments at
any time interval.
Plateletemonocyte aggregate expression (Fig. 3)
The 1-min post-exercise result for the aspirineplacebo
treatment (22.3%; IQR: 19.5e34.1% positive cells) was
significantly higher (pZ 0.015) than the pre-exercise result
(20.5%; IQR: 17.3e28.6% positive cells). No statistically
significant difference was identified between the two
treatments at any time interval.
AA-induced aggregation (Fig. 4)
The pre-exercise aspirineplacebo treatment (19.6%; IQR:
13.4e23.3% aggregation) displayed significantly higher
(pZ 0.026) aggregation than the aspirinecilostazol treat-
ment (10.7%; IQR: 6.4e16.5% aggregation). At the 1-min
post-exercise interval, aggregation with the aspirine
placebo treatment (19.9%; IQR: 16.1e25.5% aggregation)
remained significantly higher (pZ 0.002) than that seen
with the aspirinecilostazol treatment (15.0%; IQR: 9.7e
20.3% aggregation). This difference between the two
treatment groups persisted at 40-min post-exercise times
Figure 1 Platelet P-selectin expression in patients treated with cilostazol and with placebo, before and after exercise. The box
extends from the 25th percentile to the 75th percentile, with a horizontal line to represent the median. The whiskers show the
highest and lowest values (*p< 0.05, Wilcoxon signed-rank test).
Figure 2 Glycoprotein Ib-IX-V expression in patients treated with cilostazol and with placebo, before and after exercise. The box
extends from the 25th percentile to the 75th percentile, with a horizontal line to represent the median. The whiskers show the
highest and lowest values (*p< 0.05, Wilcoxon signed-rank test).
Figure 3 Plateletemonocyte aggregate expression in patients treated with cilostazol and with placebo, before and after
exercise. The box extends from the 25th percentile to the 75th percentile, with a horizontal line to represent the median. The
whiskers show the highest and lowest values (*p< 0.05, Wilcoxon signed-rank test).
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Figure 4 Arachidonic-acid-induced free platelet counting aggregation in patients treated with cilostazol and with placebo,
before and after exercise. The box extends from the 25th percentile to the 75th percentile, with a horizontal line to represent the
median. The whiskers show the highest and lowest values (*p< 0.05, **p< 0.01, Wilcoxon signed-rank test).
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IQR: 8.4e19.8% aggregation) remaining below that of the
aspirineplacebo group (17.6%; IQR: 13.1e23.5% aggrega-
tion). There were no significant changes in aggregation
following exercise in either treatment groups.
Spontaneous platelet aggregation (Fig. 5)
There was no significant difference between the treat-
ments at any time interval. There was no significant change
in SPA following exercise for either of the treatments.
Soluble P-selectin (Fig. 6)
Cilostazol treatment was associated with a reduction in the
release of soluble P-selectin following exercise. The cil-
ostazol median pre-exercise value (65.5 pgml1; IQR:
53.7e85.3) was significantly higher than the 1-min post-
exercise value (53.6 pgml1; IQR: 48.3e69.0; pZ 0.031)Figure 5 Spontaneous platelet aggregation in patients treated w
box extends from the 25th percentile to the 75th percentile, with a
highest and lowest values. No significant difference was identifiedand the 40-min post-exercise (56.7 pg ml1; IQR: 50.8e
65.2; pZ 0.046). Interestingly, the cilostazol 1-min value
was also lower than the placebo 1-min value (60.4 pg ml1;
IQR: 51.8e77.7; pZ 0.046). The same effect was not seen
between the cilostazol and the placebo pre-exercise values
(64.98 pg ml1; IQR: 50.4e75.8; pZ 0.848).
Discussion
Previous multicentre trials have shown cilostazol to
improve claudication distance.1,2 This study focused on the
effects of cilostazol on platelet activation only. The indi-
vidual effects of aspirin and cilostazol on markers of
platelet activation have been studied in various pop-
ulations. Benefits in secondary cardiovascular prevention
have been shown amongst patients with coronary and
cerebrovascular disease.5e9 The antiplatelet effect of
combination therapy with cilostazol has been studied in
patients with ischaemic heart disease (IHD), and twoith cilostazol and with placebo, before and after exercise. The
horizontal line to represent the median. The whiskers show the
between any of the groups (Wilcoxon signed-rank test).
Figure 6 Soluble P-selectin expression in patients treated with cilostazol and with placebo, before and after exercise. The box
extends from the 25th percentile to the 75th percentile, with a horizontal line to represent the median. The whiskers show the
highest and lowest values (*p< 0.05, Wilcoxon signed-rank test).
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cilostazol therapy inhibited platelet aggregation to
a greater degree than aspirin monotherapy.15,16 To date, no
work has been published documenting the effect of
combination therapy on platelets in PAD patients subjected
to exercise.
The effect of cilostazol on platelet surface P-selectin
expression has previously been studied both in vitro and in
vivo. Benefits have been identified in populations subjected
to coronary stenting.17 Furthermore, cilostazol on its own
and when administered with dipyridamole has been seen to
reduce platelet-surface P-selectin expression in patients
with arteriosclerosis obliterans.18 The ability of cilostazol
to inhibit agonist-induced expression of P-selectin is also
well documented in ex vivo studies.4,19 The results from the
current study failed to show a benefit in the baseline
expression of P-selectin with combined aspirin and cil-
ostazol treatment. However, a clear benefit was seen
following exercise, whereby the exercise-induced P-selec-
tin expression seen with aspirin/placebo therapy was pre-
vented by cilostazol/aspirin combination therapy. The
mechanism of exercise-induced platelet activation remains
a topic of debate and is probably a combination of
ischaemicereperfusion injury, sheer stress as blood flows
through stenotic lesions and catecholamine release.20 Ex
vivo studies have shown cilostazol to inhibit sheer stress-
induced expression of P-selectin, and this would be
consistent with the benefit following exercise noted in this
study.21 At least one ex vivo study has shown cilostazol to
be superior to aspirin in suppressing P-selectin expression
following sheer stress.21 Hence, the effect of combination
treatment seen herein may be predicted by the results of
ex vivo studies and explained by the effect cilostazol has on
sheer-induced platelet P-selectin expression.
The significant decrease found in GP Ib-IX-V receptor
expression confirms platelet activation following exercise.
The change was seen earlier, appeared to be greater and
more strongly significant with aspirin compared to aspirin/
cilostazol combination treatment. The effect of cilostazol
on GPIb-IX-V expression has not been previously studied. The
results of this study suggest that some benefit may begained, but further work is needed to define the role of
cilostazol in the absence of aspirin. As with P-selectin, PMAs
were seen to increase significantly following exercise in
those treated with aspirin monotherapy. This effect was not
seen with combination treatment. The similarities seen here
with the P-selectin results are to be expected as P-selectin is
an important ligand facilitating the plateletemonocyte
interaction. The role and mechanism of cilostazol suppres-
sion of plateleteleucocyte aggregate formation have been
suggested in at least one other study.22
The effect of cilostazol on platelet aggregation has been
previously studied, both in isolation and in combination
with other antiplatelet agents. Cilostazol has been shown
to inhibit the aggregation response to various agonists in
blood from healthy individuals, CAD and PAD
patients.18,23,24 Similar effects have also been described
with aspirin.23,25 The effect of combination treatment with
aspirin and cilostazol has been investigated in patients with
IHD by Tanigawa et al. Aggregation studies demonstrated
that combination treatment significantly inhibited AA-
induced aggregation.15,16 However, Mallikaarjun et al.
produced different results in a population of healthy indi-
viduals with no additive benefit seen on AA-induced
aggregation.26 The results published by Tanigawa et al. are
comparable to the baseline results seen in the population
of PAD patients in the current study, with a significant
improvement in AA-induced aggregation. The benefit seen
in AA-induced aggregation was maintained at all time
intervals. The presence of cilostazol may augment the
inhibitory effect of aspirin upon the cyclo-oxygenase
pathway, an effect which is not overcome by the exercise-
induced stress.
In this study, combination treatment had no significant
benefit over aspirin monotherapy on SPA. As previously
mentioned, SPA represents the aggregation induced by in
vitro sheer stress. Other studies involving cilostazol have
measured sheer stress using the free platelet counting
method but with variations in the turbidometric method-
ology, thus making comparisons difficult. Sheer stress-
induced platelet aggregation (SIPA) has been shown to be
inhibited by individual aspirin and cilostazol treatment and
610 M. Cleanthis et al.cilostazol/aspirin combination therapy.16,21 Neither of
these studies used proven PAD patients, and comparisons
with this PAD population are made difficult by the differ-
ences in methodology.
This study has shown that combination treatment with
cilostazol and aspirin inhibits exercise-induced platelet
aggregation (mediated by the AA pathway) significantly
more than aspirin therapy alone. This benefit may repre-
sent a synergistic antiplatelet effect produced by combi-
nation therapy and has significant clinical implications. The
increased risk of bleeding seen with clopidogrel and aspirin
has not been demonstrated with cilostazol and aspirin.10
Further benefits may include the prevention of myointimal
hyperplasia by inhibiting vascular smooth muscle prolifer-
ation.6,10,27 Hence, combination therapy offers potential
secondary prevention benefits without increased bleeding
risk. Furthermore, combination therapy with aspirin and
cilostazol may offer some benefit in preventing the platelet
activation associated with repeated exercise.
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